Found 2,508 articles
Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer
Abeona Therapeutics Inc. announced the appointment of Max Colao as Chief Commercial Officer.
Vertex Reports Second-Quarter 2018 Financial Results
Second-quarter 2018 total CF product revenues of $750 million, a 46% increase compared to $514 million in the second quarter of 2017
Locus Biosciences acquires EpiBiome's high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics
Acquisition significantly accelerates development of new products targeting antibiotic-resistant pathogens and microbiome indications
Shares of CRISPR Therapeutics (-8 percent), Editas Medicines (-5 percent) and Intellia Therapeutics (-6.7 percent) are all plunging following the release of a report that claimed CRISPR-Cas9 gene editing may cause some dangerous side effects.
July 13 Research Roundup: Gene Therapy for Cholesterol, Beta-Thalassemia, and Kidney Disease, and...
7/13/2018There are plenty of great scientific research stories out this week. Here’s a look at just a few of them from gene therapy for cholesterol to kidney disease and more.
Inscripta Granted Patents for CRISPR Gene-Editing Systems
New data shows Inscripta's MADzymes edit in mammalian cells
Abingworth Closes on $315 Million Fund Aimed at Life Science Companies in Europe and the U.S.
7/9/2018Abingworth Bioventures closed out its latest investment fund aimed at supporting life science companies with $315 million. The latest fund, ABV VII, will be used to support investments in Europe and the United States.
10 Women Biotech CEOs Lead the Charge
6/26/2018The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives.
The U.S. Patent and Trademark Office (USPTO) granted Emmanuelle Charpentier, co-founder of ERS Genomics, the University of California and University of Vienna, their first U.S. patent covering the use of CRISPR/Cas9 for gene editing.
USPTO Awards Patent to Hunterian Medicine for Technology That Delivers CRISPR Into Human Cells
Hunterian Medicine LLC, has developed groundbreaking CRISPR delivery technology for which the United States Patent and Trademark Office has granted a patent (No. 9,907,863).
Doudna-Charpentier Team Awarded Patent for CRISPR-Cas9
Invention will accelerate development of human therapeutics and improvements in food security
U.S. Patent Office Grants First Charpentier/Doudna Patent Covering CRISPR/Cas9 Gene Editing
The patent covers the use of an optimized guide RNA format in all environments including human cells.
Japanese Patent Office Grants Broad Claims Covering CRISPR/Cas9 Gene Editing Technology
ERS Genomics announced today that the Japanese Patent Office has granted Dr. Emmanuelle Charpentier, ERS Genomics’ co-founder, together with the University of California and University of Vienna, its first Japanese patent
Benchling Raises $14.5M From Benchmark to Advance Life Sciences Research
Announces 500% ARR Growth and more than 100,000 scientists using its platform
Now, two studies published in Nature Medicine suggest that CRISPR may lead to cancer unintentionally.
Merck KGaA, Darmstadt, Germany Drives Thought Leadership in Ethical Gene Editing
Merck KGaA, Darmstadt, Germany, announced that The American Journal of Bioethics has accepted a novel publication on ethical issues in genome editing to be printed in its July issue.
Microbiome Company Seed™ Launches to Disrupt Probiotics, Set New Industry Standards
Developed by Leading Scientists, Seed Launches Daily Synbiotic™ as First Flagship Product
Shares of CRISPR Therapeutics plunged dramatically Wednesday after the U.S. Food and Drug Administration placed a clinical hold on a planned sickle cell disease treatment the company was in the process of developing with Vertex Pharmaceuticals.
ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to NMI and NMI TT Pharmaservices
NMI and NMI TT Pharmaservices gain non-exclusive access to ERS Genomics’ CRISPR/Cas9 patents to expand their custom cell-based research service offerings.
Casebia Therapeutics Appoints Amy Jennings to Head Its Regulatory Affairs
Casebia Therapeutics, a biopharmaceutical company dedicated to the creation of life-transforming therapeutics through gene-editing technology, has appointed Amy Jennings, Ph.D., as its head of Regulatory Affairs.